Eos Energy stock falls after Fuzzy Panda issues short report
DUBLIN - Goldman Sachs & Co. LLC disclosed its trading activity in Avadel Pharmaceuticals PLC shares, revealing positions held as of October 29, 2025, according to a regulatory filing released Thursday.
The investment bank reported holding long positions totaling 1,703,802 shares, representing approximately 1.74% of Avadel’s outstanding shares. This includes 1,463,834 relevant securities and 239,968 derivatives. Goldman Sachs also disclosed short positions of 633,491 shares, accounting for about 0.65% of the company’s shares.
The filing, made under Rule 38.5(b) of the Irish Takeover Panel Act, details numerous purchase and sale transactions conducted on October 29. The majority of purchases were executed at prices ranging from $18.67 to $18.95 per share, with transaction sizes varying from single shares to blocks of 9,020 shares.
The disclosure also documented several securities lending transactions, including new loans of 53,435 shares and 56,003 shares, as well as new borrowings of 188,800 shares and 53,435 shares. Additionally, the filing reported several loan returns and borrow returns.
In derivatives transactions, Goldman Sachs reduced long positions in contracts for difference (CFDs) by a total of 60,891 shares at a price of $18.88 per unit.
The bank identified itself as an advisor to Avadel Pharmaceuticals in the filing, which was submitted in compliance with Irish takeover regulations requiring disclosure of dealings by connected exempt principal traders.
The information was provided based on a regulatory press release statement filed with the London Stock Exchange’s news service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.